PolyMedix, Inc.

Basic Information

170 N. Radnor-Chester Road
RADNOR, PA, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 621470033
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 16


  1. Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): Malaria is a global disease causing gt 500 million clinical cases and gt 1 million deaths each year. Moreover, drug resistant Plasmodium falciparum has become a m ...

    SBIR Phase II 2012 Department of Health and Human Services
  2. A Topical Host Defense Peptide Mimetic for Oral Mucositis

    Amount: $161,376.00

    DESCRIPTION (provided by applicant): Oral ulcerative mucositis is a common, painful, dose-limiting toxicity of chemotherapy and radiation therapy for cancer, and represents an important unmet clinica ...

    SBIR Phase I 2012 Department of Health and Human Services
  3. A Novel Antimicrobial Mimetic for Oral Candidiasis

    Amount: $975,997.00

    DESCRIPTION (provided by applicant): Oral infections of Candida albicans represent an increasing problem in human health. In immunocompromised individuals, especially those suffering from AIDS, candia ...

    SBIR Phase II 2010 Department of Health and Human Services
  4. Biomimetics for treating biofilm-embedded infections

    Amount: $749,860.00

    Multi-drug resistant (MDR) biofilms are one of the most difficult bacterial infections to treat. Current antibiotics are increasingly unable to cure these infections; underscoring the need to develop ...

    STTR Phase II 2010 Army Department of Defense
  5. Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib

    Amount: $999,094.00

    DESCRIPTION (provided by applicant): Malaria is a global disease causing gt 500 million clinical cases and gt 1 million deaths each year. Moreover, drug resistant Plasmodium falciparum has become a m ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. SBIR Phase I:Development of Novel Antimicrobial Sutures

    Amount: $150,000.00

    This Small Business Innovation Research (SBIR) Phase I project is aimed at the development of antimicrobial sutures containing an active agent that displays broad activity against pathogens associated ...

    SBIR Phase I 2010 National Science Foundation
  7. Biomimetics for treating biofilm-embedded infections

    Amount: $749,860.00

    Multi-drug resistant (MDR) biofilms are one of the most difficult bacterial infections to treat. Current antibiotics are increasingly unable to cure these infections; underscoring the need to develop ...

    STTR Phase II 2010 Army Department of Defense
  8. Novel Antibacterial Agents

    Amount: $69,891.00

    The need for novel antibiotics is well understood by anyone familiar to the field. We have discovered a novel class of antibiotics that are structurally unique from all previously known antibiotics a ...

    STTR Phase I 2009 Navy Department of Defense
  9. Biomimetics for treating biofilm-embedded infections

    Amount: $100,000.00

    Multi-drug resistant (MDR) biofilms are perhaps the most difficult bacterial infections to fight. They require novel antibiotics that operate through new mechanisms which overcome the biofilm environ ...

    STTR Phase I 2009 Army Department of Defense
  10. Development of biomimetic oligomers as anticoagulant antagonists

    Amount: $923,075.00

    DESCRIPTION (provided by applicant): LMWHs are being used with greater frequency to treat deep vein thrombosis, unstable angina, and acute pulmonary embolism, as well as thromboprophylaxis agents in a ...

    SBIR Phase II 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government